Paricalcitol Tablet

Paricalcitol Tablet

Product Showcase
Paricalcitol Tablet
Paricalcitol Tablet

Information

Paricalcitol Tablet is an oral finished dosage form product being developed for the treatment of secondary hyperparathyroidism. The reference product is Zemplar® Capsule, and YS Life Science is developing a tablet dosage form as a differentiated product concept. This product is designed to offer a tablet alternative to the existing soft capsule product, supported by YS Life Science’s in-house API capability. The tablet dosage form may provide advantages in product handling, manufacturing, and portfolio differentiation for partners seeking specialty products in the endocrine and renal disease area. *Key highlights: Oral tablet alternative to existing soft capsule products Developed for secondary hyperparathyroidism 1 mcg and 2 mcg strengths In-house API capability BE expected in 2026 Q3 Approval expected in 2027 Q4 Launch expected in 2028 Q2
YS Life ScienceE21YS Life Science’s highest priority is the top quality of APIs and FDFs. Our products are manufactured in compliance with ICH guidelines and exported worldwide, including the US, EU, and Japan. With approvals from USFDA, European, and Japanese authorities, we ensure strict quality control and regulatory compliance. We are also seeking FDF partners in Southeast Asia for long-term cooperation.

Log in

See all the content and easy-to-use features by logging in or registering!